AKRON, Ohio, Nov. 3, 2025 /PRNewswire/ — The Goodyear Tire & Rubber Company (NASDAQ: GT) (“Goodyear” or the “Company”) has completed the previously announced divestiture of the majority of its Goodyear Chemical business to an affiliate of Gemspring Capital Management,…
Goodyear Forward delivered $185 million of segment operating income benefits in the quarter. All planned divestitures completed, driving significant deleveraging.
CHARLOTTE, N.C., Nov. 3, 2025 /PRNewswire/ — JELD-WEN Holding, Inc. (NYSE: JELD) (“JELD-WEN” or the “Company”) today announced results for the three and nine months ended September 27, 2025. Comparability is to the same period in the prior year.
CHARLOTTE, N.C., Nov. 3, 2025 /PRNewswire/ — JELD-WEN Holding, Inc. (NYSE: JELD), a leading global manufacturer of building products, today announced it has initiated a comprehensive review of strategic alternatives for its Europe business.
Continued strong production and solid earnings; Increasing 2027 ROE target by 50 basis points
PITTSBURGH, Nov. 3, 2025 /PRNewswire/ — Howmet Aerospace Inc. (“Howmet Aerospace” or the “Company”) (NYSE: HWM) today announced that it has priced its underwritten public offering of $500 million aggregate principal amount of its 4.550% Notes due 2032 (the “New…
SECAUCUS, N.J., Nov. 3, 2025 /PRNewswire/ — Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company’s strategy, performance and the latest market…
Collaboration Focuses on Next-Generation Design, Efficiency, and Scalability for AI Computing Infrastructure
ST. PAUL, Minn., Nov. 3, 2025 /PRNewswire/ — Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, Nov. 12, 2025, beginning at approximately 11:20 a.m. EST in New York,…
Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.1Survival benefit: Treatment…